Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$21.33 +2.8%	$17.10	$9.57 ▼ $27.34	$2.95B	0.94	2.27 million shs	2.65 million shs
IMVT Immunovant	$15.24 +2.7%	$16.38	$12.72 ▼ $34.47	$2.66B	0.66	1.35 million shs	1.40 million shs
KNSA Kiniksa Pharmaceuticals International	$33.75 +0.5%	$29.78	$17.82 ▼ $34.55	$2.50B	0.14	705,288 shs	356,168 shs
OXBDF Oxford BioMedica	$7.35	$5.30	$3.15 ▼ $7.35	$778.82M	1.08	960 shs	47 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	0.00%	+4.00%	+31.18%	+40.98%	-15.49%
IMVT Immunovant	0.00%	+0.13%	-16.81%	+5.39%	-53.05%
KNSA Kiniksa Pharmaceuticals International	0.00%	+1.11%	+25.46%	+25.51%	+27.70%
OXBDF Oxford BioMedica	0.00%	+9.41%	+42.17%	+87.18%	+57.22%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARWR Arrowhead Pharmaceuticals	3.7639 of 5 stars	3.5	1.0	0.0	3.4	2.8	2.5	0.0
IMVT Immunovant	2.9993 of 5 stars	4.4	2.0	0.0	0.0	2.7	1.7	0.0
KNSA Kiniksa Pharmaceuticals International	2.682 of 5 stars	2.5	3.0	0.0	0.0	3.4	3.3	0.6
OXBDF Oxford BioMedica	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	3.00	Buy	$43.14	102.26% Upside
IMVT Immunovant	2.83	Moderate Buy	$35.20	130.97% Upside
KNSA Kiniksa Pharmaceuticals International	3.00	Buy	$41.17	21.98% Upside
OXBDF Oxford BioMedica	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest OXBDF, ARWR, IMVT, and KNSA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	IMVT Immunovant	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $37.00
8/12/2025	IMVT Immunovant	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$33.00 ➝ $30.00
8/11/2025	IMVT Immunovant	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/11/2025	ARWR Arrowhead Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/11/2025	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00
8/8/2025	ARWR Arrowhead Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$40.00 ➝ $38.00
7/29/2025	KNSA Kiniksa Pharmaceuticals International	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $54.00
7/28/2025	ARWR Arrowhead Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/28/2025	IMVT Immunovant	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$17.00 ➝ $18.00
7/21/2025	KNSA Kiniksa Pharmaceuticals International	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$36.00
7/10/2025	IMVT Immunovant	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold	$18.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$572.98M	5.15	N/A	N/A	$3.76 per share	5.67
IMVT Immunovant	N/A	N/A	N/A	N/A	$3.49 per share	N/A
KNSA Kiniksa Pharmaceuticals International	$423.24M	5.91	N/A	N/A	$6.68 per share	5.05
OXBDF Oxford BioMedica	$111.34M	6.99	N/A	N/A	$1.01 per share	7.28

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.28	N/A	N/A	N/A	N/A	-40.91%	-11.62%	N/A
IMVT Immunovant	-$413.84M	-$2.85	N/A	N/A	N/A	N/A	-80.99%	-72.23%	11/6/2025 (Estimated)
KNSA Kiniksa Pharmaceuticals International	-$43.19M	$0.04	843.96	135.00	N/A	0.90%	1.05%	0.80%	11/4/2025 (Estimated)
OXBDF Oxford BioMedica	-$195.90M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Latest OXBDF, ARWR, IMVT, and KNSA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q1 2026	IMVT Immunovant	-$0.69	-$0.60	+$0.09	-$0.71	N/A	N/A
8/7/2025	Q3 2025	ARWR Arrowhead Pharmaceuticals	-$0.94	-$1.26	-$0.32	-$1.26	$29.01 million	$27.77 million
7/29/2025	Q2 2025	KNSA Kiniksa Pharmaceuticals International	$0.18	$0.23	+$0.05	$0.23	$145.21 million	$156.80 million
5/29/2025	Q4 2025	IMVT Immunovant	-$0.72	-$0.64	+$0.08	-$0.64	N/A	$0.16 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A
OXBDF Oxford BioMedica	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	0.39	4.87	4.87
IMVT Immunovant	N/A	12.32	12.32
KNSA Kiniksa Pharmaceuticals International	N/A	3.57	3.16
OXBDF Oxford BioMedica	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
IMVT Immunovant	47.08%
KNSA Kiniksa Pharmaceuticals International	53.95%
OXBDF Oxford BioMedica	N/A

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	4.30%
IMVT Immunovant	1.80%
KNSA Kiniksa Pharmaceuticals International	53.48%
OXBDF Oxford BioMedica	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.26 million	132.31 million	Optionable
IMVT Immunovant	120	174.32 million	171.18 million	Optionable
KNSA Kiniksa Pharmaceuticals International	220	74.11 million	34.48 million	Optionable
OXBDF Oxford BioMedica	891	105.96 million	N/A	Not Optionable

OXBDF, ARWR, IMVT, and KNSA Headlines

Recent News About These Companies

Oxford BioMedica (OTCMKTS:OXBDF) Reaches New 12-Month High - Should You Buy?

August 23 at 7:05 AM | marketbeat.com

Oxford Biomedica Director’s Share Transaction Error and Resolution

August 22 at 10:50 AM | tipranks.com

Oxford Biomedica shares rise after £60m primary raise

August 19, 2025 | globalcapital.comG

Oxford BioMedica (OTCMKTS:OXBDF) Sets New 1-Year High - Here's What Happened

August 17, 2025 | marketbeat.com

Oxford Biomedica’s Chair Increases Stake with Significant Share Purchase

August 15, 2025 | msn.com

Oxford BioMedica raises GBP60 million to fund US expansion

August 15, 2025 | lse.co.uk

CDMO OXB raises £60M to support US expansion ambitions

August 15, 2025 | fiercepharma.comF

Oxford Biomedica raises £60m at small discount

August 15, 2025 | proactiveinvestors.co.uk

Oxford Biomedica Raises £60 Million to Expand US Operations

August 15, 2025 | tipranks.com

Oxford BioMedica (OTCMKTS:OXBDF) Shares Gap Down - Should You Sell?

August 14, 2025 | marketbeat.com

Oxford BioMedica (OTCMKTS:OXBDF) Trading Down 0.6% - Here's Why

August 14, 2025 | marketbeat.com

Oxford BioMedica (OTCMKTS:OXBDF) Reaches New 1-Year High - Still a Buy?

August 6, 2025 | marketbeat.com

Oxford BioMedica (OTCMKTS:OXBDF) Hits New 52-Week High - Time to Buy?

July 31, 2025 | marketbeat.com

Oxford BioMedica holds outlook as revenue jumps and order book boosted

July 28, 2025 | lse.co.uk

UK's Oxford Biomedica sees first-half sales surging on strong order book

July 28, 2025 | reuters.com

UK's Oxford Biomedica maintains annual outlook

July 28, 2025 | reuters.com

Oxford BioMedica completes purchase of last 10% stake in US subsidiary

June 23, 2025 | lse.co.uk

Oxford BioMedica touts strong first-half momentum ahead of meeting

June 11, 2025 | lse.co.uk

Oxford Biomedica Full Year 2024 Earnings: EPS Beats Expectations

May 1, 2025 | finance.yahoo.com

Oxford BioMedica (OXBDF) Receives a Buy from RBC Capital

April 15, 2025 | theglobeandmail.com

When Will Oxford Biomedica plc (LON:OXB) Turn A Profit?

April 10, 2025 | uk.finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OXBDF, ARWR, IMVT, and KNSA Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$21.33 +0.58 (+2.80%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$21.35 +0.02 (+0.08%)

As of 08/22/2025 06:00 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Immunovant NASDAQ:IMVT

$15.24 +0.40 (+2.70%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$15.26 +0.02 (+0.10%)

As of 08/22/2025 06:26 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$33.75 +0.17 (+0.51%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$33.44 -0.31 (-0.92%)

As of 08/22/2025 07:05 PM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Oxford BioMedica OTCMKTS:OXBDF

$7.35 0.00 (0.00%)

As of 08/22/2025

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time